02/11/2026
Excited about new options for equine cushings disease! We just got some on the shelves and are excited to give it a try.
Dechra is excited to announce the FDA approval of ZygolideĀ® (pergolide tablets) for the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease) in horses.
Learn more: https://bit.ly/4qcWa6A
Package Insert:https://www.dechra-us.com//Files/Files/ProductDownloads/US/Zygolide-Marketing-Insert-85-x-11-1-mg-Aenova-5-1-NL.pdf
IMPORTANT SAFETY INFORMATION:
As with all drugs, side effects may occur. ZygolideĀ® (pergolide tablets) is for use in horses only. Zygolide has not been evaluated in breeding, pregnant or lactating horses. Treatment with Zygolide may cause loss of appetite. Most cases are mild. If severe, a temporary dose reduction may be necessary. Weight loss, lack of energy, and behavioral changes also may be observed. Zygolide tablets should not be crushed due to the potential for increased human exposure. Pregnant or lactating women should wear gloves when administering this product. Zygolide is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. Keep Zygolide in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten Zygolide tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest Zygolide tablets. Refer to the prescribing information for complete details or visit www.dechra-us.com.
This product is only available in the US at this time. This communication may contain information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration, or usage in the country of your origin.